Table 1 Baseline demographic data and cumulative clinical and serological data of the study cohort
SLE (n = 26) | Rhupus syndrome (n = 9) | Jaccoud’s arthropathy (n = 10) | NDNE (n = 7) | |
|---|---|---|---|---|
Age (mean ± SD) | 49.4 ± 16.0 | 41.1 ± 5.7 | 61.3 ± 14.3 | 43.1 ± 16.5 |
Disease duration (mean ± SD) | 15.6 ± 8.2 | 13.7 ± 6.7 | 21.7 ± 8.5 | 10.8 ± 4.5 |
Gender, female, n | 26 | 9 | 10 | 7 |
Cumulative 1997 ACR criteria | ||||
Malar rash | 12 (46.2) | 5 (55.5) | 4 (40.0) | 3 (42.8) |
Discoid rash | 2 (7.7) | 0 | 1 (10.0) | 1 (14.3) |
Photosensitivity | 4 (15.4) | 1 (11.1) | 2 (20.0) | 1 (14.3) |
Oral/nasopharyngeal ulcers | 2 (7.7) | 0 | 1 (10.0) | 1 (14.3) |
Serositis | 15 (57.7) | 4 (44.4) | 8 (80.0) | 3 (42.8) |
Renal disorders | 5 (19.2) | 0 | 2 (20.0) | 3 (42.8) |
Neurologic disorders | 2 (7.7) | 0 | 2 (20.0) | 0 |
Hematological disorders | 14 (53.8) | 5 (55.5) | 7 (70.0) | 2 (28.6) |
ANA | 26 (100) | 9 (100) | 10 (100) | 7 (100) |
Anti-dsDNA | 18 (69.2) | 6 (66.7) | 8 (80.0) | 4 (57.1) |
Antiphospholipid antibodies | 7 (26.9) | 3 (33.3) | 3 (30.0) | 1 (14.3) |
Other laboratory findings | ||||
Anti-Ro/SSA | 14 (53.8) | 4 (44.4) | 5 (50.0) | 5 (71.4) |
Anti-La/SSB | 2 (7.7) | 0 | 1 (10.0) | 1 (14.3) |
Anti-RNP | 2 (7.7) | 0 | 0 | 2 (28.6) |
Anti-Sm | 2 (7.7) | 0 | 0 | 2 (28.6) |
Rheumatoid factor | 11 (37.9) | 7 (77.8) | 1 (10.0) | 3 (42.8) |
Anti-CCP | 7 (26.9) | 6 (66.7) | 0 | 1 (14.3) |
SLICC/damage index (mean ± SD) | 1.4 ± 1.3 | 1.4 ± 0.5 | 2.6 ± 1.3 | 0.6 ± 0.5 |
Medication receiveda | ||||
Total corticosteroid dose >50 g | 15 (57.7) | 3 (33.3) | 10 (100) | 2 (28.6) |
Antimalarial agents | 25 (96.1) | 8 (88.9) | 10 (100) | 7 (100) |
Methotrexate | 20 (76.9) | 9 (100) | 6 (60.0) | 5 (71.4) |
Azathioptine | 7 (26.9) | 1 (11.1) | 4 (40.0) | 2 (28.6) |
Micophenolate | 4 (15.4) | 1 (11.1) | 1 (10.0) | 2 (28.6) |
Rituximab | 8 (30.7) | 4 (44.4) | 2 (20.0) | 2 (28.6) |
Belimumab | 1 (3.8) | 0 | 0 | 1 (14.3) |
Anti TNF-alpha | 3 (11.5) | 3(33.3) | 0 | 0 |
Anti IL-6 | 2 (7.7) | 1 (11.1) | 1 (10.0) | 0 |